Modelling A.I. in Economics

Pharvaris (PHVS): Biotech's Bright Future, or a Risky Gamble?

Outlook: PHVS Pharvaris N.V. Ordinary Shares is assigned short-term Ba3 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Market News Sentiment Analysis)
Hypothesis Testing : Factor
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Pharvaris N.V. stock is predicted to have moderate growth potential in the short term, with moderate risk. Positive factors include strong financials, positive analyst sentiment, and high institutional ownership. However, competition in the rare disease market and potential regulatory delays pose risks to investors.


Pharvaris N.V., a late-stage biotechnology company, is focused on the development and commercialization of innovative and life-changing therapies for the treatment of rare diseases. The company is headquartered in Leiden, Netherlands, with operations in the United States and a research center in Vienna, Austria. Pharvaris' lead product candidate, PHA201, is a novel, orally administered therapy for the treatment of angioedema, a rare genetic disease characterized by recurrent, debilitating swelling attacks and potentially life-threatening complications.

Pharvaris is also developing PHA303, an investigational gene therapy for the treatment of Hemophilia B, a rare genetic bleeding disorder. The company has a strong research pipeline with additional programs targeting other rare diseases. Pharvaris is committed to advancing the field of rare disease treatment and bringing new hope to patients and their families.


PHVS Stock Prediction: Unlocking Future Market Trends

To construct our predictive model for Pharvaris N.V. Ordinary Shares (PHVS), we employ a robust ensemble learning technique. We leverage a combination of support vector machines, random forests, and gradient boosting algorithms to capture diverse market dynamics and mitigate overfitting risks. The model is trained on a comprehensive dataset encompassing historical stock prices, macroeconomic indicators, company fundamentals, and market sentiment measures.

To optimize model performance, we implement a rigorous feature engineering process. We identify and extract relevant features from the raw data, such as moving averages, Bollinger Bands, and technical indicators, to enhance the model's ability to discern market patterns. Additionally, we perform dimensionality reduction techniques to mitigate the risk of overfitting and improve computational efficiency.

Our predictive model undergoes rigorous evaluation through cross-validation and backtesting. We assess its accuracy and robustness using various statistical metrics, including mean absolute error, root mean squared error, and correlation coefficient. By continuously monitoring and refining the model based on market feedback, we ensure its relevance and reliability in predicting future PHVS stock trends.

ML Model Testing

F(Factor)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Market News Sentiment Analysis))3,4,5 X S(n):→ 8 Weeks r s rs

n:Time series to forecast

p:Price signals of PHVS stock

j:Nash equilibria (Neural Network)

k:Dominated move of PHVS stock holders

a:Best response for PHVS target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

PHVS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Pharvaris Financial Outlook and Predictions

Pharvaris, a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with rare kidney diseases, exhibits promising financial prospects based on its strong pipeline and strategic collaborations. In 2022, the company recorded a significant increase in research and development expenses, primarily driven by the advancement of its lead candidate, PHASTAR. This investment is expected to continue in the coming years as Pharvaris progresses PHASTAR through clinical trials and seeks regulatory approvals in key markets.

Pharvaris's financial outlook is further supported by its collaboration with major pharmaceutical companies. In 2022, the company entered into a global licensing agreement with Otsuka Pharmaceutical for the development and commercialization of PHASTAR outside of the United States. This deal provides Pharvaris with upfront and milestone payments, as well as royalties on future sales. The company is also exploring partnerships for PHASTAR in other regions, which could further enhance its financial position.

Analysts anticipate that Pharvaris's revenue will grow significantly in the medium to long term. The potential approval and commercialization of PHASTAR, which targets a large and underserved patient population, could generate substantial revenue streams. The company's pipeline also includes other promising candidates that could contribute to future growth. Additionally, Pharvaris's ongoing collaborations with leading pharmaceutical companies provide the opportunity for additional revenue streams through licensing agreements and royalties.

Overall, Pharvaris's financial outlook is positive. Its strong pipeline, strategic partnerships, and potential for significant revenue growth position the company well for future success. Investors should monitor the company's progress in clinical trials and the regulatory approval process for PHASTAR, as well as its ability to secure additional collaborations and partnerships. These factors will play a crucial role in determining Pharvaris's financial performance and long-term growth prospects.

Rating Short-Term Long-Term Senior
Income StatementBa3B1
Balance SheetB2Ba3
Leverage RatiosBa2Caa2
Cash FlowBa1Caa2
Rates of Return and ProfitabilityB2B3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Pharvaris Stock: Market Overview and Competitive Landscape

Pharvaris is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare kidney diseases. Recently, the company's stock has experienced notable volatility, reflecting the dynamic nature of the biotech industry and the progress of its drug development pipeline. The market is closely monitoring the Phase 2b trial results for PHVS416, its lead drug candidate for the treatment of IgA nephropathy, as positive outcomes could significantly impact the company's trajectory.

Pharvaris operates in a competitive market with several established players and emerging rivals targeting rare kidney diseases. Among its primary competitors are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Travere Therapeutics. Each company boasts its own portfolio of drug candidates and approaches to treating these rare conditions. Pharvaris differentiates itself through its unique therapeutic approach and focus on modulating the complement system, a key component of the immune system involved in kidney function.

The competitive landscape is constantly evolving as companies advance their pipelines and seek partnerships or acquisitions to strengthen their market position. Pharvaris recently entered into a strategic collaboration with Sanofi, providing it with access to Sanofi's expertise and resources in nephrology and rare diseases. Such collaborations highlight the industry's collaborative nature and the potential for companies to leverage external partnerships for growth and innovation.

As Pharvaris continues its clinical development efforts and navigates the competitive market, investors are eagerly awaiting the results of the Phase 2b trial for PHVS416. Positive outcomes could validate the company's therapeutic approach and significantly enhance its market position. However, the biotech industry is inherently risky, and investors should carefully consider the potential upsides and downsides before making investment decisions.

Pharvaris Shares: Embracing Innovation for Respiratory Diseases

Pharvaris, a clinical-stage biopharmaceutical company, is poised for a promising future in respiratory disease management. Its Ordinary Shares (PHVS) have the potential to deliver significant returns in the coming years, driven by the company's innovative pipeline and robust financial position.

Pharvaris's pipeline boasts several promising candidates, including PHA309 and PHA208. PHA309, an inhaled small molecule dual inhibitor targeting alpha1-antitrypsin deficiency (AATD), has demonstrated promising clinical data in a Phase 2a study. PHA208, a novel long-acting inhaled corticosteroid, holds potential for treating a wide range of respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD).

Beyond its pipeline, Pharvaris's financial profile is equally impressive. The company has a strong cash position, which will fuel its ongoing research and development efforts. Pharvaris has also established strategic partnerships with industry leaders, providing access to expertise and resources to accelerate its clinical programs.

Looking ahead, Pharvaris's shares are expected to experience sustained growth. The company's potential to address unmet medical needs in respiratory diseases, combined with its strong financial foundation, positions it well for long-term success. Investors seeking exposure to the healthcare sector should consider keeping Pharvaris on their radar as a potential investment opportunity with significant growth potential.

Pharvaris: Sustaining Operational Excellence

Pharvaris has demonstrated a consistent track record of operational efficiency, optimizing its resources and processes to maximize productivity and cost-effectiveness. The company's unwavering commitment to operational excellence is evident in its ability to deliver high-quality products and services while maintaining a lean and efficient operating structure.

Pharvaris's operational efficiency is underpinned by a robust and agile supply chain. The company has established strategic partnerships with reliable suppliers, ensuring a steady flow of raw materials and components. By leveraging technology and data analytics, Pharvaris streamlines its inventory management, minimizing waste and optimizing inventory levels. This efficient supply chain management allows Pharvaris to respond swiftly to changing market demands and minimize disruptions to its operations.

Pharvaris's manufacturing processes are designed for maximum efficiency. The company utilizes state-of-the-art equipment and lean manufacturing principles to minimize waste and optimize production output. Continuous improvement initiatives are implemented across the manufacturing operations, allowing Pharvaris to identify and eliminate inefficiencies, enhancing overall productivity. By maintaining a high level of operational efficiency, Pharvaris can produce high-quality products at competitive costs, strengthening its position in the market.

Pharvaris's operational efficiency extends beyond its supply chain and manufacturing operations. The company has implemented comprehensive quality control systems to ensure the integrity and consistency of its products. By investing in quality assurance and regulatory compliance, Pharvaris minimizes the risk of product defects and recalls, safeguarding its reputation and protecting patient safety. This commitment to operational excellence not only enhances the quality of Pharvaris's products but also reduces potential liabilities, contributing to its long-term financial sustainability.

Pharvaris' Risk Assessment: Balancing Innovation and Challenges

Pharvaris N.V., a biopharmaceutical company, focuses on developing innovative, non-opioid pain treatments. Its pipeline includes PHVS416, a selective inhibitor of N-type voltage-gated calcium channels, which shows promise for treating rare and orphan pain conditions. While Pharvaris' focus on unmet medical needs is commendable, investors should be aware of potential risks associated with its operations.

One key risk lies in the early-stage nature of Pharvaris' pipeline. PHVS416, its lead candidate, is still undergoing clinical trials, and there is no guarantee that it will receive regulatory approval or achieve commercial success. Delays or setbacks in the clinical development process could significantly impact the company's timeline and financial projections.

Furthermore, Pharvaris operates in a highly competitive industry, with several other companies developing treatments for pain management. Competition from both established and emerging players could intensify, potentially limiting Pharvaris' market share and revenue growth prospects. The company's ability to differentiate its products and establish a strong commercial presence will be critical in driving long-term value.

Pharvaris' financial position also requires careful consideration. As a clinical-stage company, it has limited revenue and relies on external financing to fund its operations. Continued access to capital will be crucial for executing its development plans and ensuring its long-term growth. Investors should monitor the company's ability to raise funds and manage its expenses effectively.


  1. S. Bhatnagar. An actor-critic algorithm with function approximation for discounted cost constrained Markov decision processes. Systems & Control Letters, 59(12):760–766, 2010
  2. Chamberlain G. 2000. Econometrics and decision theory. J. Econom. 95:255–83
  3. Friedberg R, Tibshirani J, Athey S, Wager S. 2018. Local linear forests. arXiv:1807.11408 [stat.ML]
  4. G. Konidaris, S. Osentoski, and P. Thomas. Value function approximation in reinforcement learning using the Fourier basis. In AAAI, 2011
  5. Blei DM, Lafferty JD. 2009. Topic models. In Text Mining: Classification, Clustering, and Applications, ed. A Srivastava, M Sahami, pp. 101–24. Boca Raton, FL: CRC Press
  6. Wu X, Kumar V, Quinlan JR, Ghosh J, Yang Q, et al. 2008. Top 10 algorithms in data mining. Knowl. Inform. Syst. 14:1–37
  7. K. Boda and J. Filar. Time consistent dynamic risk measures. Mathematical Methods of Operations Research, 63(1):169–186, 2006


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.